drugset / Trial / NCT01019850
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Phase 1
Completed
27 enrolled
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane I 131 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma.
Timeline
- Start
- 2010-03
- Primary completion
- 2014-12
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 150 mg/m2 | Oral |
| Subject | Vorinostat | Small molecule | 180 mg/m2 | Oral |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |
| Background | filgrastim | Protein / enzyme biologic | — | — |